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Dear Editor,
Retinal capillary hemangiomas (RCH) are capillary angio-
matous hamartomas of the retina and optic nerve head. The
median age of diagnosing the disease is 31 years old [1].
Although most RCH is isolated, 10–30% in the 31–40 age
group are associated with Von Hippel Lindau disease
(VHL). Up to 15% of RCHs are juxtapapillary, where most
are located temporally [2]. They are often associated with
epiretinal membrane (ERM) formation and serous and
tractional retinal detachment of the macula, which leads to
a poor prognosis [1].
We report a typical case of isolated juxtapapillary RCH
that underwent successful combined therapy with intra-
vitreal ranibizumab injection and photodynamic therapy
(PDT) 1 week before PPV and ERM peeling surgery.
A 32-year-old woman presented with reduced right eye
vision and metamorphopsia for 3 months. At presentation,
her best-corrected visual acuity was 20/50 and 20/25 for the
right and left eyes, respectively. Right eye fundus exami-
nation revealed a reddish mass measuring 2.0 × 1.5 mm in
the inferotemporal juxtapapillary region associated with
macular subretinal fluid and ERM (Fig. 1a).
Fundus fluorescein angiogram (FFA) showed early
filling of the lesion with late leakage into the subretinal
space. Anomalous vascular channels were seen sprout-
ing from the lesion (Fig. 1b). Optical coherence tom-
ography (OCT) confirmed serous detachment of the
macula with vitreomacular traction (Fig. 1c). Central
foveal thickness was increased to 570 µm (normal
values=<315 µm) [3].
A diagnosis of juxtapapillary retinal capillary hemangio-
ma was made. Systemic workup for Von Hippel Lindau
(VHL) disease did not reveal any other tumors. Her visual
acuity continued to deteriorate to 20/100 in the subsequent
2 months. She was treated once with PDT using standard
fluence at that time, with reduced diameter laser spot
centering on the lesion avoiding the optic disc. There was
no clinical response and her vision continued to deteriorate
to 20/200 3 months after the initial PDT. Combined therapy,
using standard fluence PDT and intravitreal injection of
ranibizumab were performed 2 months later (7 months since
presentation). Reduction of lesion size (1.5 × 1.5 mm) and
vascularity was noted 1 day after the combined therapy
(Fig. 2a). One week later, PPV and ERM peel were carried
out and intravitreal triamcinolone injection (2 mg in
0.05 ml) was given at the conclusion of surgery.
The patient's visual acuity improved to 20/25 after
successful surgery and the lesion remained stable for
12 months, up to the latest follow-up (Fig. 2b). The central
foveal thickness remained reduced within normal limits at
324 μm. FFA showed hyperfluorescence in the late phase
(Fig. 2c). A small superotemporal branch retinal vein
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resolved spontaneously.
Discussion
To date, no single modality in the treatment of
juxtapapillary RCH has been particularly effective [1].
Laser photocoagulation applied to the neural tissue
surrounding the tumor can cause permanent scotomas
[2]. Use of cryotherapy is limited due to the posterior
location of the lesion.
Anti-vascular endothelial growth factor (anti-VEGF)
therapy has been reported to reduce vascular permeability
by altering the balance of vaso-active cytokines like nitric
Fig. 2 Imaging results (color fundus photography and FFA) of the
patient after combined treatment with injection of ranibizumab, PDT,
and intravitreal surgery. a Day 1 after combined intravitreal
ranibizumab injection and PDT, showing regression of the tumor as
well as marked decrease in vascularity and exudation. b Post-operative
(month 2) fundus photograph showing relief of traction on the macula
after removal of the epiretinal membrane and reduction in size of the
angioma. A peripheral branch retinal vein occlusion (white arrows)
resulted from a small iatrogenic break. c Late phase of fundus
flourescein angiography (month 12) showing staining of the lesion
with minimal leakage
Fig. 1 Imaging results (color fundus photography, FFA and OCT) of
the patient at initial presentation. a Fundus photograph of the right eye
showing juxtapapillary retinal capillary hemangioma, measured 2.0×
1.5 mm, located inferotemporal to the optic disc. b Fundus fluorescein
angiography demonstrating hyperflourescence of the lesion as well as
late leakage into submacular space. c OCT (horizontal 5-mm scan
across the fovea) showing macular detachment secondary to vitre-
omacular traction
626 Graefes Arch Clin Exp Ophthalmol (2011) 249:625–627oxide and endothelin-1 [4] or by directly altering endothe-
lial tight junction proteins [5]. It is postulated that excessive
accumulation of hypoxic induced factor (HIF) in the
neoplastic stromal cells of RCH leads to the production of
other angiogenic factors that are able to maintain and
promote the growth of primary hemangiomas [6].
PDT is shown to be effective in causing fibrosis and
involution of the primary angioma, but its use on peri-
papillary area is limited by vaso-occlusive effects [2, 7].
For larger tumors, verteporfin may only be activated on
the surface of the tumor, and the reactive oxygen species
may not cause closure of deeper tumor vessels. By
combining anti-VEGF with reduced fluence PDT, the
outline of the primary angioma can be better delineated
and may thus reduce the energy and the treatment area,
thereby minimizing the damage to the neurological tissues
[8]. Recent reports of combined therapy with anti-VEGF
therapy and PDT have shown promising results in these
lesions [7].
Anti-VEGF agents, like bevacizumab, have been
reported as a useful pre-operative adjunct in the surgical
treatment of proliferative diabetic retinopathy, with signif-
icant reduction in neovascularization, bleeding, and adher-
ence of fibrovascular complex to the retina [9]. We found
that ranibizumab is useful in the present case. Combined
treatment with anti-VEGF and PDT 1 week before surgery
caused a reduction in macular edema, which reduced the
risk of retinal cyst rupture during peeling procedure [10].
Reduced tumor vascularization may have lowered the risk
of intraoperative bleeding.
In summary, pre-operative combination therapy with an
anti-VEGF agent and PDT, PPV, and ERM followed by
intravitreal triamcinolone at the conclusion of surgery led to
improvement in visual outcome. The use of triple therapy
was recently shown to be effective in the treatment of age-
related macular degeneration and our case may suggest that
a multi-faceted approach could be beneficial in cases of
juxtapapillary RCH [11].
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